.jpg)
1 hour ago
3
Article content
- The MOTheR and CONCORDIA studies show HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer delivers outcomes comparable to online hemodiafiltration
- Theranova dialyzer’s unique design removes large-middle molecules associated with inflammation, cardiovascular disease and other comorbidities, helping achieve filtration closer to the natural kidney
- Findings are further supported by recent data showing HDx therapy is associated with reduced resource utilization, including lower per-session costs and reduced water consumption compared to HDF in provider-based analyses
- HDx therapy supports a modern, coordinated approach to kidney care by expanding access to clinically differentiated hemodialysis without the need for additional infrastructure
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) — Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized controlled MOTheR trial and interim results from the real-world CONCORDIA study were presented at the 63rd European Renal Association (ERA) Congress, held June 3-6, 2026, in Glasgow, Scotland.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
While both therapies have shown survival benefits over conventional hemodialysis,3,4
HDx therapy offers a practical alternative to OL-HDF because it can be delivered using existing hemodialysis equipment without additional specialized infrastructure or nurse training. HDx therapy utilizes a medium cut-off membrane that efficiently removes large-middle molecules, allowing for filtration closer to that of the natural kidney.5,6,7,8,9,10,11 These large-middle molecules have been linked to inflammation, cardiovascular disease, and other comorbidities in dialysis patients.5-7,11
Article content
Article content
“The MOTheR HDx trial provides the first randomized controlled evidence showing that expanded hemodialysis with medium cut-off membranes performs as well as online hemodiafiltration for cardiovascular and mortality outcomes,” said Patricia de Sequera MD, PhD, nephrology service chief, Hospital Universitario Infanta Leonor, Madrid. “Based on my experience as a practicing physician, this establishes HDx as a clinically valid option, giving nephrologists a technically simpler alternative backed by robust evidence to guide individualized treatment decisions in routine practice.”
Article content
Beyond the newly presented studies, a recent provider-perspective analysis from Spain suggests HDx therapy may reduce resource utilization compared with OL-HDF. The study reports per-session cost savings of approximately 8%–18% and approximately 20% lower water consumption, supporting the potential of HDx as a resource-efficient option within modern dialysis care.12
Article content
“Collectively, these data reinforce the growing body of evidence supporting HDx therapy as a clinically differentiated and practical option within modern kidney care,” said Peter Rutherford, M.B. BS, Ph.D., head of Worldwide Medical, Vantive. “They also bring sharper focus to a patient-centric approach to kidney care; one built around a coordinated care pathway that prioritizes PD when possible and uses clinically differentiated hemodialysis options, such as HDx therapy, when chosen by the patient or needed for clinical reasons.”
English (US)